---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-23-000110"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:57:59.347934+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics raises ~$110M via public offering of 6.47M shares at $17/sh

## Summary
- Entered underwriting agreement with Goldman Sachs, Morgan Stanley, and Wells Fargo to sell 6,470,588 shares at $17.00/share.
- Underwriters have a 30-day option to purchase up to 970,588 additional shares.
- Offering closed on November 13, 2023; net proceeds after underwriting discounts and commissions not specified.
- Prospectus supplement filed under automatic shelf registration statement (File No. 333-275396).

## SEC filing metadata
- accession: 0000899923-23-000110
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992323000110/0000899923-23-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992323000110/mygn-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-23-000110
- JSON: https://secwatch.observer/filing/0000899923-23-000110.json
- Plain text: https://secwatch.observer/filing/0000899923-23-000110.txt

## Key facts
- Material Agreements
  MYRIAD GENETICS INC entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC (effective 2023-11-08).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC
  - Effective: 2023-11-08
  source text: On November 8, 2023, Myriad Genetics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC (the “Underwriters”), relating to the issuance and sale pursuant to an underwritten public offering (the “Offering”) of an aggregate of 6,470,588 shares (the “Shares”) of its common stock, par value $0.01 per share (the “Common Stock”), and up to 970,588 additional shares of Common Stock at the Underwriters’ option.
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992323000110/0000899923-23-000110-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.